These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Preprints are manuscripts made publicly available before they have been submitted for formal peer review and publication. They might contain new research findings or data. Preprints can be a draft or final version of an author's research but must not have been accepted for publication at the time of submission.
submitted on 13.02.2020 and posted on 13.02.2020by Julia Guzy, Shatadru Chakravarty, Foster Buchanan, Haoran Chen, Jeffrey M. Gaudet, Jeremy Hix, Christiane L. Mallett, Erik Shapiro
Magnetic particle imaging (MPI) is an exciting new biomedical imaging technology that uses superparamagnetic nanoparticles as an imaging tracer. MPI is touted as a quantitative imaging modality but MPI signal properties have never been characterized for nanoparticles undergoing biodegradation. Here we characterize the nature of the MPI signal properties as a function of degradation of various magnetic particle formulations. We show that MPI signal properties can increase or decrease as a function of nanoparticle formulation and chemical environment and that long-term in vitro experiments only roughly approximate long-term in vivo MPI signal properties. Data are supported by electron microscopy of nanoparticle degradation. Knowledge of MPI signal property changes during nanoparticle degradation will be critical in design and interpretation of all MPI experiments. Further, we demonstrate for the first time, an environmentally sensitive MPI contrast mechanism opening the door to smart contrast paradigms in MPI.
Authors Chakravarty and Shapiro have pending patents on the PLGA-encapsualted iron oxide nanoparticles described herein and Shapiro is Founder and President of Shape Scientific, supplier of the iron oxide nanocrystals and CLIPs used in these studies.